Evidence map›Paper›PMID 38275910›Full record

ReviewCancers2024

Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.

Youssef Al Hmada, Robert T Brodell, Naji Kharouf, Thomas W Flanagan, Abdulhadi A Alamodi, Sofie-Yasmin Hassan, Hosam Shalaby, Sarah-Lilly Hassan, Youssef Haikel, Mosaad Megahed and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Youssef Al HmadaDepartment of Pathology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.
Robert T BrodellDepartment of Pathology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.
Naji KharoufInstitut National de la Santé et de la Recherche Médicale, University of Strasbourg, 67000 Strasbourg, France.ORCID 0000-0001-6768-138X
Thomas W FlanaganDepartment of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA 70112, USA.
Abdulhadi A AlamodiCollege of Health Sciences, Jackson State University, 310 W Woodrow Wilson Ave Ste 300, Jackson, MS 39213, USA.
Sofie-Yasmin HassanDepartment of Pharmacy, Faculty of Science, Heinrich-Heine University Duesseldorf, 40225 Dusseldorf, Germany.
Hosam ShalabyDepartment of Urology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Sarah-Lilly HassanDepartment of Chemistry, Faculty of Science, Heinrich-Heine University Duesseldorf, 40225 Dusseldorf, Germany.
Youssef HaikelInstitut National de la Santé et de la Recherche Médicale, University of Strasbourg, 67000 Strasbourg, France.
Mosaad MegahedClinic of Dermatology, University Hospital of Aachen, 52074 Aachen, Germany.
Simeon SantourlidisEpigenetics Core Laboratory, Medical Faculty, Institute of Transplantation Diagnostics and Cell Therapeutics, Heinrich Heine University Düsseldorf, 40225 Dusseldorf, Germany.ORCID 0000-0002-0743-5336
Mohamed HassanInstitut National de la Santé et de la Recherche Médicale, University of Strasbourg, 67000 Strasbourg, France.ORCID 0000-0002-0336-6425
Heinrich Heine University Düsseldorf · DEInserm · FRState Street (United States) · USTulane University · USJackson State University · USLouisiana State University Health Sciences Center New Orleans · USUniversitätsklinikum Aachen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is the third most common type of skin cancer, characterized by its heterogeneity and propensity to metastasize to distant organs. Melanoma is a heterogeneous tumor, composed of genetically divergent subpopulations, including a small fraction of melanoma-initiating cancer stem-like cells (CSCs) and many non-cancer stem cells (non-CSCs). CSCs are characterized by their unique surface proteins associated with aberrant signaling pathways with a causal or consequential relationship with tumor progression, drug resistance, and recurrence. Melanomas also harbor significant alterations in functional genes (BRAF, CDKN2A, NRAS, TP53, and NF1). Of these, the most common are the BRAF and NRAS oncogenes, with 50% of melanomas demonstrating the BRAF mutation (BRAF

Indexed as

BRAFCSCsMAPKmelanomaPI3K

Identifiers

PMID38275910
PMCPMC10814963
OpenAlexW4391098890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.